[Should drug-induced gynecomastia be monitored?].
Nicolas
X
X
Granier
H
H
Grippari
J L
JL
Bergez
C
C
Laborde
J P
JP
Talarmin
F
F
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy; D005260:Female; D006177:Gynecomastia / Q000139:chemically induced*; D006801:Humans; D007049:Iatrogenic Disease
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone
Faut-il surveiller une gynécomastie médicamenteuse?